Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

ClinicalTrials.gov Identifier: NCT03972488

Novartis Reference Number: CAAA601A22301

Last Update: Mar 07, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

The aim of NETTER-2 is to determine if Lutathera in combination with long-acting octreotide prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients are eligible, as well as patients previously treated with SSAs in the absence of progression.

Condition 
Gastro-enteropancreatic Neuroendocrine Tumor
Phase 
Phase 3
Overall status 
Recruiting
Start date 
Jan 22, 2020
Completion date 
Oct 30, 2027
Gender 
All
Age(s)
15 Years and older (Child, Adult, Older Adult)

Interventions

Drug
Lutathera
7.4 GBq/200 mCi x 4 administrations every 8 +/- 1 weeks
Drug
long-acting octreotide
30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment
Drug
high dose long-acting octreotide
60 mg every 4 weeks
Other
Optional post-progression re-treatment with Lutathera
additional 2-4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles)
Other
Optional post-progression cross-over to Lutathera
maximum 4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles) plus octreotide long-acting (30 mg every 8 weeks)
Drug
Lutathera
7.4 GBq/200 mCi x 4 administrations every 8 +/- 1 weeks
Drug
long-acting octreotide
30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment
Drug
high dose long-acting octreotide
60 mg every 4 weeks
Other
Optional post-progression re-treatment with Lutathera
additional 2-4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles)
Other
Optional post-progression cross-over to Lutathera
maximum 4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles) plus octreotide long-acting (30 mg every 8 weeks)
Drug
Lutathera
7.4 GBq/200 mCi x 4 administrations every 8 +/- 1 weeks
Drug
long-acting octreotide
30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment
Drug
high dose long-acting octreotide
60 mg every 4 weeks
Other
Optional post-progression re-treatment with Lutathera
additional 2-4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles)
Other
Optional post-progression cross-over to Lutathera
maximum 4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles) plus octreotide long-acting (30 mg every 8 weeks)
Drug
Lutathera
7.4 GBq/200 mCi x 4 administrations every 8 +/- 1 weeks
Drug
long-acting octreotide
30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment
Drug
high dose long-acting octreotide
60 mg every 4 weeks
Other
Optional post-progression re-treatment with Lutathera
additional 2-4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles)
Other
Optional post-progression cross-over to Lutathera
maximum 4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles) plus octreotide long-acting (30 mg every 8 weeks)

Eligibility Criteria

Inclusion Criteria:

Presence of metastasized or locally advanced, inoperable (curative intent) histologically proven, well differentiated Grade 2 or Grade 3 gastroenteropancreatic neuroendocrine (GEP-NET) tumor diagnosed within 6 months prior to screening.
Ki67 index ≥10 and ≤ 55%
Patients ≥ 15 years of age and a body weight of > 40 kg at screening
Expression of somatostatin receptors on all target lesions documented by CT/MRI scans, assessed by any of the following somatostatin receptor imaging (SRI) modalities within 3 months prior to randomization: [68Ga]-DOTA-TOC (e.g. Somakit-TOC®) PET/CT (or MRI when applicable based on target lesions) imaging, [68Ga]-DOTA-TATE PET/CT (or MRI when applicable based on target lesions) imaging (e.g. NETSPOT®), Somatostatin Receptor scintigraphy (SRS) with [111In]-pentetreotide (Octreoscan® SPECT/CT), SRS with [99mTc]-Tektrotyd, [64Cu]-DOTA-TATE PET/CT (or MRI when applicable based on target lesions) imaging.
The tumor uptake observed in the target lesions must be > normal liver uptake.
Karnofsky Performance Score (KPS) ≥ 60
Presence of at least 1 measurable site of disease
Patients who have provided a signed informed consent form to participate in the study, obtained prior to the start of any protocol related activities

Exclusion Criteria:

Creatinine clearance < 40 mL/min calculated by the Cockroft Gault method
Hb concentration < 5.0 mmol/L (<8.0 g/dL); WBC < 2x10E9/L (2000/mm3); platelets < 75x10E9/L (75x10E3/mm3)
Total bilirubin > 3 x ULN
Serum albumin < 3.0 g/dL unless prothrombin time is within the normal range
Pregnancy or lactation
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, are not allowed to participate in this study UNLESS they are using highly effective methods of contraception throughout the study treatment period (including cross-over and re-treatment, if applicable) and for 6 months after study drug discontinuation
Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization in the study.
Documented RECIST progression to previous treatments for the current GEP-NET at any time prior to randomization
Patients for whom in the opinion of the investigator other therapeutic options (eg chemo-, targeted therapy) are considered more appropriate than therapy offered in the study, based on patient and disease characteristics
Any previous therapy with Interferons, Everolimus (mTOR-inhibitors), chemotherapy or other systemic therapies for GEP-NET administered for more than 1 month or within 12 weeks prior to randomization in the study.
Any previous radioembolization, chemoembolization and radiofrequency ablation for GEP-NET
Any surgery within 12 weeks prior to randomization in the study
Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to screening in the study. Patients with a history of brain metastases must have a head CT or MRI with contrast to document stable disease prior to randomization in the study.
Uncontrolled congestive heart failure (NYHA II, III, IV). Patients with history of congestive heart failure who do not violate this exclusion criterion will undergo an evaluation of their cardiac ejection fraction prior to randomization via echocardiography. The results from an earlier assessment (not exceeding 30 days prior to randomization) may substitute the evaluation at the discretion of the Investigator, if no clinical worsening is noted. The patient's measured cardiac ejection fraction in these patients must be ≥40% before randomization.
QTcF > 470 msec for females and QTcF > 450 msec for males or congenital long QT syndrome
Uncontrolled diabetes mellitus as defined by hemoglobin A1c value > 7.5%
Hyperkaleamia > 6.0 mmol/L (CTCAE Grade 3) which is not corrected prior to study enrolment
Any patient receiving treatment with short-acting octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of Lutathera, or any patient receiving treatment with SSAs (e.g. octreotide long-acting), which cannot be interrupted for at least 6 weeks before the administration of Lutathera.
Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study.
Prior external beam radiation therapy to more than 25% of the bone marrow.
Current spontaneous urinary incontinence
Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years
Patient with known incompatibility to CT Scans with IV contrast due to allergic reaction or renal insufficiency. If such a patient can be imaged with MRI, then the patient would not be excluded.
Hypersensitivity to any somatostatin analogues, the IMPs active substance or to any of the excipients.
Patients who have participated in any therapeutic clinical study/received any investigational agent within the last 30 days

Study Locations

United States
Yale Cancer Center
Recruiting
New Haven, 06520 - Connecticut
Contact: Pamela Kunz, Dr
United States
USF - H. Lee Moffitt Cancer Center and Research Institute
Recruiting
Tampa, 33612 - Florida
Contact: Jonathan Strosberg, Dr
United States
University of Iowa Hospitals and Clinics - Oncology
Recruiting
Iowa City, 52242 - Iowa
Contact: David Bushnell, Dr
United States
University of Kentucky UK Markey Cancer Center
Recruiting
Lexington, 40536 - Kentucky
Contact: Aman Chauhan, Dr
United States
Mayo Clinic - Oncology
Recruiting
Rochester, 55905 - Minnesota
Contact: Thorvardur Halfdanarson, Dr
United States
Nebraska Cancer Centers
Recruiting
Omaha, 68130 - Nebraska
Contact: Samuel Mehr, Dr
United States
MD Anderson Cancer Center
Recruiting
Houston, 77030 - Texas
Contact: Daniel Halperin, Dr
United States
Yale Cancer Center
Recruiting
New Haven, 06520 - Connecticut
Contact: Pamela Kunz, Dr
United States
USF - H. Lee Moffitt Cancer Center and Research Institute
Recruiting
Tampa, 33612 - Florida
Contact: Jonathan Strosberg, Dr
United States
University of Iowa Hospitals and Clinics - Oncology
Recruiting
Iowa City, 52242 - Iowa
Contact: David Bushnell, Dr
United States
University of Kentucky UK Markey Cancer Center
Recruiting
Lexington, 40536 - Kentucky
Contact: Aman Chauhan, Dr
United States
Mayo Clinic - Oncology
Recruiting
Rochester, 55905 - Minnesota
Contact: Thorvardur Halfdanarson, Dr
United States
Nebraska Cancer Centers
Recruiting
Omaha, 68130 - Nebraska
Contact: Samuel Mehr, Dr
United States
MD Anderson Cancer Center
Recruiting
Houston, 77030 - Texas
Contact: Daniel Halperin, Dr
United States
Yale Cancer Center
Recruiting
New Haven, 06520 - Connecticut
Contact: Pamela Kunz, Dr
United States
USF - H. Lee Moffitt Cancer Center and Research Institute
Recruiting
Tampa, 33612 - Florida
Contact: Jonathan Strosberg, Dr
United States
University of Iowa Hospitals and Clinics - Oncology
Recruiting
Iowa City, 52242 - Iowa
Contact: David Bushnell, Dr
United States
University of Kentucky UK Markey Cancer Center
Recruiting
Lexington, 40536 - Kentucky
Contact: Aman Chauhan, Dr
United States
Mayo Clinic - Oncology
Recruiting
Rochester, 55905 - Minnesota
Contact: Thorvardur Halfdanarson, Dr
United States
Nebraska Cancer Centers
Recruiting
Omaha, 68130 - Nebraska
Contact: Samuel Mehr, Dr
United States
MD Anderson Cancer Center
Recruiting
Houston, 77030 - Texas
Contact: Daniel Halperin, Dr
United States
Yale Cancer Center
Recruiting
New Haven, 06520 - Connecticut
Contact: Pamela Kunz, Dr
United States
USF - H. Lee Moffitt Cancer Center and Research Institute
Recruiting
Tampa, 33612 - Florida
Contact: Jonathan Strosberg, Dr
United States
University of Iowa Hospitals and Clinics - Oncology
Recruiting
Iowa City, 52242 - Iowa
Contact: David Bushnell, Dr
United States
University of Kentucky UK Markey Cancer Center
Recruiting
Lexington, 40536 - Kentucky
Contact: Aman Chauhan, Dr
United States
Mayo Clinic - Oncology
Recruiting
Rochester, 55905 - Minnesota
Contact: Thorvardur Halfdanarson, Dr
United States
Nebraska Cancer Centers
Recruiting
Omaha, 68130 - Nebraska
Contact: Samuel Mehr, Dr
United States
MD Anderson Cancer Center
Recruiting
Houston, 77030 - Texas
Contact: Daniel Halperin, Dr
United States
Canada
London Health Sciences Centre, University of Western Ontario - Oncology
Recruiting
London,
Contact: David Laidley, Dr
Canada
Centre Hospitalier Universitaire de Quebec
Recruiting
Quebec,
Contact: Francois-Alexandre Buteau, Dr
Canada
Sunnybrook Health Sciences Centre
Recruiting
Toronto,
Contact: Sten Myrehaug, Dr
Canada
BC Cancer Agency
Recruiting
Vancouver,
Contact: Jonathan Loree, Dr
Canada
London Health Sciences Centre, University of Western Ontario - Oncology
Recruiting
London,
Contact: David Laidley, Dr
Canada
Centre Hospitalier Universitaire de Quebec
Recruiting
Quebec,
Contact: Francois-Alexandre Buteau, Dr
Canada
Sunnybrook Health Sciences Centre
Recruiting
Toronto,
Contact: Sten Myrehaug, Dr
Canada
BC Cancer Agency
Recruiting
Vancouver,
Contact: Jonathan Loree, Dr
Canada
London Health Sciences Centre, University of Western Ontario - Oncology
Recruiting
London,
Contact: David Laidley, Dr
Canada
Centre Hospitalier Universitaire de Quebec
Recruiting
Quebec,
Contact: Francois-Alexandre Buteau, Dr
Canada
Sunnybrook Health Sciences Centre
Recruiting
Toronto,
Contact: Sten Myrehaug, Dr
Canada
BC Cancer Agency
Recruiting
Vancouver,
Contact: Jonathan Loree, Dr
Canada
London Health Sciences Centre, University of Western Ontario - Oncology
Recruiting
London,
Contact: David Laidley, Dr
Canada
Centre Hospitalier Universitaire de Quebec
Recruiting
Quebec,
Contact: Francois-Alexandre Buteau, Dr
Canada
Sunnybrook Health Sciences Centre
Recruiting
Toronto,
Contact: Sten Myrehaug, Dr
Canada
BC Cancer Agency
Recruiting
Vancouver,
Contact: Jonathan Loree, Dr
Canada
France
CHU Paris Nord-Val de Seine
Recruiting
Clichy,
Contact: Philippe Ruszniewski
France
Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot
Recruiting
Lyon,
Contact: Catherine Lombard-Bohas
France
Institut du Cancer de Montpellier - Oncology
Recruiting
Montpellier,
Contact: Emmanuel Deshayes, Dr
France
CHU-Hôtel Dieu Service de Médecine Nucléaire
Recruiting
Nantes,
Contact: Catherine Ansquer, Dr
France
Institut Gustave Roussy
Recruiting
Villejuif,
Contact: Eric Baudin, Dr
France
CHU Paris Nord-Val de Seine
Recruiting
Clichy,
Contact: Philippe Ruszniewski
France
Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot
Recruiting
Lyon,
Contact: Catherine Lombard-Bohas
France
Institut du Cancer de Montpellier - Oncology
Recruiting
Montpellier,
Contact: Emmanuel Deshayes, Dr
France
CHU-Hôtel Dieu Service de Médecine Nucléaire
Recruiting
Nantes,
Contact: Catherine Ansquer, Dr
France
Institut Gustave Roussy
Recruiting
Villejuif,
Contact: Eric Baudin, Dr
France
CHU Paris Nord-Val de Seine
Recruiting
Clichy,
Contact: Philippe Ruszniewski
France
Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot
Recruiting
Lyon,
Contact: Catherine Lombard-Bohas
France
Institut du Cancer de Montpellier - Oncology
Recruiting
Montpellier,
Contact: Emmanuel Deshayes, Dr
France
CHU-Hôtel Dieu Service de Médecine Nucléaire
Recruiting
Nantes,
Contact: Catherine Ansquer, Dr
France
Institut Gustave Roussy
Recruiting
Villejuif,
Contact: Eric Baudin, Dr
France
CHU Paris Nord-Val de Seine
Recruiting
Clichy,
Contact: Philippe Ruszniewski
France
Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot
Recruiting
Lyon,
Contact: Catherine Lombard-Bohas
France
Institut du Cancer de Montpellier - Oncology
Recruiting
Montpellier,
Contact: Emmanuel Deshayes, Dr
France
CHU-Hôtel Dieu Service de Médecine Nucléaire
Recruiting
Nantes,
Contact: Catherine Ansquer, Dr
France
Institut Gustave Roussy
Recruiting
Villejuif,
Contact: Eric Baudin, Dr
France
Germany
Universitätsklinikum Erlangen
Recruiting
Erlangen,
Contact: Marianne Pavel, Prof
Germany
Universitätsklinikum Essen - Klinik für Nuklearmedizin
Recruiting
Essen,
Contact: Ken Hermann, Prof
Germany
Klinikum rechts der Isar Technische Universität München
Recruiting
München,
Contact: Klemens Scheidhauer, Prof
Germany
Universitätsklinikum Erlangen
Recruiting
Erlangen,
Contact: Marianne Pavel, Prof
Germany
Universitätsklinikum Essen - Klinik für Nuklearmedizin
Recruiting
Essen,
Contact: Ken Hermann, Prof
Germany
Klinikum rechts der Isar Technische Universität München
Recruiting
München,
Contact: Klemens Scheidhauer, Prof
Germany
Universitätsklinikum Erlangen
Recruiting
Erlangen,
Contact: Marianne Pavel, Prof
Germany
Universitätsklinikum Essen - Klinik für Nuklearmedizin
Recruiting
Essen,
Contact: Ken Hermann, Prof
Germany
Klinikum rechts der Isar Technische Universität München
Recruiting
München,
Contact: Klemens Scheidhauer, Prof
Germany
Universitätsklinikum Erlangen
Recruiting
Erlangen,
Contact: Marianne Pavel, Prof
Germany
Universitätsklinikum Essen - Klinik für Nuklearmedizin
Recruiting
Essen,
Contact: Ken Hermann, Prof
Germany
Klinikum rechts der Isar Technische Universität München
Recruiting
München,
Contact: Klemens Scheidhauer, Prof
Germany
Italy
A.O.di Bologna Policl.S.Orsola
Recruiting
Bologna,
Contact: Davide Campana, Dr
Italy
University of Genova - Oncology
Recruiting
Genova,
Contact: Diego Ferone, Dr
Italy
Istituto Oncologico Romagnolo
Recruiting
Meldola,
Contact: Stefano Severi, Dr
Italy
Fondazione Irccs Istituto Nazionale Tumori
Recruiting
Milano,
Contact: Ettore Seregni, Dr
Italy
Ieo, Irccs
Recruiting
Milano,
Contact: Nicola Fazio, Dr
Italy
IRCCS fondazione Pascale - Oncology
Recruiting
Napoli,
Contact: Salvatore Tafuto, Dr
Italy
Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology
Recruiting
Reggio Emilia,
Contact: Annibale Versari, Dr
Italy
Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology
Recruiting
Roma,
Contact: Francesco Panzuto, Dr
Italy
A.O.di Bologna Policl.S.Orsola
Recruiting
Bologna,
Contact: Davide Campana, Dr
Italy
University of Genova - Oncology
Recruiting
Genova,
Contact: Diego Ferone, Dr
Italy
Istituto Oncologico Romagnolo
Recruiting
Meldola,
Contact: Stefano Severi, Dr
Italy
Fondazione Irccs Istituto Nazionale Tumori
Recruiting
Milano,
Contact: Ettore Seregni, Dr
Italy
Ieo, Irccs
Recruiting
Milano,
Contact: Nicola Fazio, Dr
Italy
IRCCS fondazione Pascale - Oncology
Recruiting
Napoli,
Contact: Salvatore Tafuto, Dr
Italy
Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology
Recruiting
Reggio Emilia,
Contact: Annibale Versari, Dr
Italy
Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology
Recruiting
Roma,
Contact: Francesco Panzuto, Dr
Italy
A.O.di Bologna Policl.S.Orsola
Recruiting
Bologna,
Contact: Davide Campana, Dr
Italy
University of Genova - Oncology
Recruiting
Genova,
Contact: Diego Ferone, Dr
Italy
Istituto Oncologico Romagnolo
Recruiting
Meldola,
Contact: Stefano Severi, Dr
Italy
Fondazione Irccs Istituto Nazionale Tumori
Recruiting
Milano,
Contact: Ettore Seregni, Dr
Italy
Ieo, Irccs
Recruiting
Milano,
Contact: Nicola Fazio, Dr
Italy
IRCCS fondazione Pascale - Oncology
Recruiting
Napoli,
Contact: Salvatore Tafuto, Dr
Italy
Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology
Recruiting
Reggio Emilia,
Contact: Annibale Versari, Dr
Italy
Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology
Recruiting
Roma,
Contact: Francesco Panzuto, Dr
Italy
A.O.di Bologna Policl.S.Orsola
Recruiting
Bologna,
Contact: Davide Campana, Dr
Italy
University of Genova - Oncology
Recruiting
Genova,
Contact: Diego Ferone, Dr
Italy
Istituto Oncologico Romagnolo
Recruiting
Meldola,
Contact: Stefano Severi, Dr
Italy
Fondazione Irccs Istituto Nazionale Tumori
Recruiting
Milano,
Contact: Ettore Seregni, Dr
Italy
Ieo, Irccs
Recruiting
Milano,
Contact: Nicola Fazio, Dr
Italy
IRCCS fondazione Pascale - Oncology
Recruiting
Napoli,
Contact: Salvatore Tafuto, Dr
Italy
Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology
Recruiting
Reggio Emilia,
Contact: Annibale Versari, Dr
Italy
Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology
Recruiting
Roma,
Contact: Francesco Panzuto, Dr
Italy
Korea, Republic of
Seoul National University Bundang Hospital
Recruiting
Seongnam-Si,
Contact: Jin Won Kim
Korea, Republic of
Asan Medical Center - Oncology
Recruiting
Seoul,
Contact: Baek-Yeol Ryoo, Dr
Korea, Republic of
Seoul National University Hospital - Department of Internal Medicine
Recruiting
Seoul,
Contact: Do-Youn Oh, Dr
Korea, Republic of
Severance Hospital, Yonsei University Health System - Medical Oncology
Recruiting
Seoul,
Contact: Sang Joon Shin
Korea, Republic of
Seoul National University Bundang Hospital
Recruiting
Seongnam-Si,
Contact: Jin Won Kim
Korea, Republic of
Asan Medical Center - Oncology
Recruiting
Seoul,
Contact: Baek-Yeol Ryoo, Dr
Korea, Republic of
Seoul National University Hospital - Department of Internal Medicine
Recruiting
Seoul,
Contact: Do-Youn Oh, Dr
Korea, Republic of
Severance Hospital, Yonsei University Health System - Medical Oncology
Recruiting
Seoul,
Contact: Sang Joon Shin
Korea, Republic of
Seoul National University Bundang Hospital
Recruiting
Seongnam-Si,
Contact: Jin Won Kim
Korea, Republic of
Asan Medical Center - Oncology
Recruiting
Seoul,
Contact: Baek-Yeol Ryoo, Dr
Korea, Republic of
Seoul National University Hospital - Department of Internal Medicine
Recruiting
Seoul,
Contact: Do-Youn Oh, Dr
Korea, Republic of
Severance Hospital, Yonsei University Health System - Medical Oncology
Recruiting
Seoul,
Contact: Sang Joon Shin
Korea, Republic of
Seoul National University Bundang Hospital
Recruiting
Seongnam-Si,
Contact: Jin Won Kim
Korea, Republic of
Asan Medical Center - Oncology
Recruiting
Seoul,
Contact: Baek-Yeol Ryoo, Dr
Korea, Republic of
Seoul National University Hospital - Department of Internal Medicine
Recruiting
Seoul,
Contact: Do-Youn Oh, Dr
Korea, Republic of
Severance Hospital, Yonsei University Health System - Medical Oncology
Recruiting
Seoul,
Contact: Sang Joon Shin
Korea, Republic of
Netherlands
Erasmus Medisch Centrum
Recruiting
Rotterdam,
Contact: Johannes Hofland, Dr
Netherlands
UMC Utrecht - Oncology
Recruiting
Utrecht,
Contact: Marnix Lam, Prof
Netherlands
Erasmus Medisch Centrum
Recruiting
Rotterdam,
Contact: Johannes Hofland, Dr
Netherlands
UMC Utrecht - Oncology
Recruiting
Utrecht,
Contact: Marnix Lam, Prof
Netherlands
Erasmus Medisch Centrum
Recruiting
Rotterdam,
Contact: Johannes Hofland, Dr
Netherlands
UMC Utrecht - Oncology
Recruiting
Utrecht,
Contact: Marnix Lam, Prof
Netherlands
Erasmus Medisch Centrum
Recruiting
Rotterdam,
Contact: Johannes Hofland, Dr
Netherlands
UMC Utrecht - Oncology
Recruiting
Utrecht,
Contact: Marnix Lam, Prof
Netherlands
Spain
Hospital Universitario Vall d'Hebrón
Recruiting
Barcelona,
Contact: Jaume Capdevila Castill&#xF3;n, Dr
Spain
Hospital General Universitario Gregorio Marañón
Recruiting
Madrid,
Contact: Gabriela Torres, Dr
Spain
Hospital Universitario Ramón y Cajal
Recruiting
Madrid,
Contact: Teresa Alonso Gordoa, Dr
Spain
Complejo Hospitalario Universitario Santiago de Compostela
Recruiting
Santiago de Compostela,
Contact: Urbano Anido-Herr&#xE1;nz, Dr
Spain
Hospital Universitari i Politecnic La Fe
Recruiting
Valencia,
Contact: Angel Segura Huerta, Dr
Spain
Hospital Universitario Vall d'Hebrón
Recruiting
Barcelona,
Contact: Jaume Capdevila Castill&#xF3;n, Dr
Spain
Hospital General Universitario Gregorio Marañón
Recruiting
Madrid,
Contact: Gabriela Torres, Dr
Spain
Hospital Universitario Ramón y Cajal
Recruiting
Madrid,
Contact: Teresa Alonso Gordoa, Dr
Spain
Complejo Hospitalario Universitario Santiago de Compostela
Recruiting
Santiago de Compostela,
Contact: Urbano Anido-Herr&#xE1;nz, Dr
Spain
Hospital Universitari i Politecnic La Fe
Recruiting
Valencia,
Contact: Angel Segura Huerta, Dr
Spain
Hospital Universitario Vall d'Hebrón
Recruiting
Barcelona,
Contact: Jaume Capdevila Castill&#xF3;n, Dr
Spain
Hospital General Universitario Gregorio Marañón
Recruiting
Madrid,
Contact: Gabriela Torres, Dr
Spain
Hospital Universitario Ramón y Cajal
Recruiting
Madrid,
Contact: Teresa Alonso Gordoa, Dr
Spain
Complejo Hospitalario Universitario Santiago de Compostela
Recruiting
Santiago de Compostela,
Contact: Urbano Anido-Herr&#xE1;nz, Dr
Spain
Hospital Universitari i Politecnic La Fe
Recruiting
Valencia,
Contact: Angel Segura Huerta, Dr
Spain
Hospital Universitario Vall d'Hebrón
Recruiting
Barcelona,
Contact: Jaume Capdevila Castill&#xF3;n, Dr
Spain
Hospital General Universitario Gregorio Marañón
Recruiting
Madrid,
Contact: Gabriela Torres, Dr
Spain
Hospital Universitario Ramón y Cajal
Recruiting
Madrid,
Contact: Teresa Alonso Gordoa, Dr
Spain
Complejo Hospitalario Universitario Santiago de Compostela
Recruiting
Santiago de Compostela,
Contact: Urbano Anido-Herr&#xE1;nz, Dr
Spain
Hospital Universitari i Politecnic La Fe
Recruiting
Valencia,
Contact: Angel Segura Huerta, Dr
Spain
United Kingdom
Bristol Haematology and Oncology Centre
Recruiting
Bristol,
Contact: Stephen Falk, Dr
United Kingdom
Liverpool Cancer Research Uk Centre
Recruiting
Liverpool,
Contact: Sobhan Vinjamuri, Prof
United Kingdom
Guys And St Thomas Hospital
Recruiting
London,
Contact: Valerie Lewington, Prof
United Kingdom
Kings College Hospital - Oncology
Recruiting
London,
Contact: Rajaventhan Srirajaskanthan, Dr
United Kingdom
Royal Free Hospital, London
Recruiting
London,
Contact: Shaunak Navalkissoor, Dr
United Kingdom
Weston Park Hospital
Recruiting
Sheffield,
Contact: Jonathan Wadsley, Dr
United Kingdom
Bristol Haematology and Oncology Centre
Recruiting
Bristol,
Contact: Stephen Falk, Dr
United Kingdom
Liverpool Cancer Research Uk Centre
Recruiting
Liverpool,
Contact: Sobhan Vinjamuri, Prof
United Kingdom
Guys And St Thomas Hospital
Recruiting
London,
Contact: Valerie Lewington, Prof
United Kingdom
Kings College Hospital - Oncology
Recruiting
London,
Contact: Rajaventhan Srirajaskanthan, Dr
United Kingdom
Royal Free Hospital, London
Recruiting
London,
Contact: Shaunak Navalkissoor, Dr
United Kingdom
Weston Park Hospital
Recruiting
Sheffield,
Contact: Jonathan Wadsley, Dr
United Kingdom
Bristol Haematology and Oncology Centre
Recruiting
Bristol,
Contact: Stephen Falk, Dr
United Kingdom
Liverpool Cancer Research Uk Centre
Recruiting
Liverpool,
Contact: Sobhan Vinjamuri, Prof
United Kingdom
Guys And St Thomas Hospital
Recruiting
London,
Contact: Valerie Lewington, Prof
United Kingdom
Kings College Hospital - Oncology
Recruiting
London,
Contact: Rajaventhan Srirajaskanthan, Dr
United Kingdom
Royal Free Hospital, London
Recruiting
London,
Contact: Shaunak Navalkissoor, Dr
United Kingdom
Weston Park Hospital
Recruiting
Sheffield,
Contact: Jonathan Wadsley, Dr
United Kingdom
Bristol Haematology and Oncology Centre
Recruiting
Bristol,
Contact: Stephen Falk, Dr
United Kingdom
Liverpool Cancer Research Uk Centre
Recruiting
Liverpool,
Contact: Sobhan Vinjamuri, Prof
United Kingdom
Guys And St Thomas Hospital
Recruiting
London,
Contact: Valerie Lewington, Prof
United Kingdom
Kings College Hospital - Oncology
Recruiting
London,
Contact: Rajaventhan Srirajaskanthan, Dr
United Kingdom
Royal Free Hospital, London
Recruiting
London,
Contact: Shaunak Navalkissoor, Dr
United Kingdom
Weston Park Hospital
Recruiting
Sheffield,
Contact: Jonathan Wadsley, Dr
United Kingdom

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]